主题图谱 / oncology

oncology

GeneTech 知识引擎共收录 106 篇相关科研实体，横跨 19 个垂直领域。数据来自 OpenAlex、arXiv、Crossref、PubMed、Europe PMC 等公开学术源，全部可溯源到原文。

年度产出趋势

代表性文献（按质量分排序，前 60 条）

• Artificial Intelligence-Based Exosome Analysis for Improving Diagnostic Performance of Breast Lesions on Ultrasound: Protocol of a Prospective, Multicenter Cohort Study
  2026 · 医疗人工智能 · PURPOSE: Exosome-surface enhanced Raman spectroscopy-artificial intelligence platform (exosome-SERS-AI) is an innovative liquid biopsy method that acquires SERS signals from plasma exosomes and analyzes them using deep l…
• Artificial Intelligence and Radiomics for Differentiating Pseudoprogression from True Progression in High-Grade Gliomas: A Meta-Analysis
  2026 · 医疗人工智能 · Differentiating true progression (TP) from pseudoprogression (PsP) in high-grade gliomas (HGGs) on MRI is a critical clinical challenge. This meta-analysis evaluates the overall diagnostic accuracy of radiomics and artif…
• Enabling access to talicabtagene autoleucel in relapsed/refractory B-cell malignancies; multicenter real-world evidence on delivery, efficacy and safety
  2026 · 碳中和与 CCUS · Talicabtagene autoleucel (tali-cel) is the first humanized CD19-directed CAR-T cell therapy approved in India for relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-N…
• Digital twins of ex vivo human lungs enable accurate and personalized evaluation of therapeutic efficacy
  2026 · 数字孪生 · Digital twins are an emerging concept in healthcare that envisions integration of molecular, physiological, functional and clinical data to create computational models of biological systems such as cells, organs and indi…
• Abstract 6724: OncoTwin: A multimodal digital twin framework for predicting treatment response and guiding trial design in ALK-rearranged non-small-cell lung cancer.
  2026 · 数字孪生 · Abstract Introduction: Despite advances with next-generation tyrosine kinase inhibitors (TKIs), response and progression patterns in ALK-rearranged NSCLC vary widely, and currently no reliable biomarkers can predict indi…
• Updated risk stratification for lower-grade (grade 2 and 3) IDH-mutant diffuse gliomas
  2026 · 基因技术工具 · Background: The definition of a "low-grade, high-risk diffuse glioma" was established decades ago and is based largely on clinical factors such as age, tumor size, histology and qualitative extent of tumor resection. Our…
• MicroRNAs as Diagnostic and Prognostic Biomarkers in Canine Splenic Hemangiosarcoma: A Systematic Review
  2026 · 生命科学 · Background: Canine splenic hemangiosarcoma (HSA) is an aggressive malignant neoplasm associated with a poor prognosis and considerable diagnostic challenges. Differentiating HSA from non-malignant splenic lesions, partic…
• Artificial Intelligence and Radiomics for Differentiating Pseudoprogression from True Progression in High-Grade Gliomas: A Meta-Analysis
  2026 · 隐私计算与数据要素 · Differentiating true progression (TP) from pseudoprogression (PsP) in high-grade gliomas (HGGs) on MRI is a critical clinical challenge. This meta-analysis evaluates the overall diagnostic accuracy of radiomics and artif…
• Chat GPT Performance in Multi-Disciplinary Boards—Should AI Be a Member of Cancer Boards?
  2025 · AI 安全与对齐 · Background: Multidisciplinary Tumor Councils (MDTs) are vital platforms that provide tailored treatment plans for cancer patients by combining expertise from various medical disciplines. Recently, Artificial Intelligence…
• Artificial intelligence as treatment support in breast cancer: current perspectives
  2025 · AI 安全与对齐 · With the increasing amount of information related to breast cancer (BC) management, artificial intelligence (AI) has emerged as a tool with the potential to enhance the quality of treatment through the efficient integrat…
• SEOM-GEICO clinical guidelines on endometrial cancer (2025)
  2025 · 生物计算 · Endometrial cancer (EC) is the most common gynecological malignancy in developed countries. Although most cases are diagnosed at an early stage, prognosis in case of relapse or metastasis remains poor. Molecular characte…
• Neuroscience in prostate cancer
  2025 · 脑科学 · BACKGROUND: Emerging evidence in cancer neuroscience indicates that the nervous system interacts directly or indirectly with cancer cells, promoting tumor progression. The prostate gland contains an extensive neural netw…
• Chemotherapy induced neurotoxicity in cancer survivors assessed through a dual database bibliometric analysis from 2005 to 2025
  2025 · 脑科学 · BACKGROUND: Cancer survivors frequently suffer from chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-related cognitive impairment (CRCI), two of the most common and persistent adverse effects of antican…
• Clinicopathological and prognostic significance of DDX41 mutation in myeloid neoplasms: a systematic review and meta-analysis.
  2025 · 碳中和与 CCUS · DDX41 is one of the most frequently altered genes in familial acute myeloid leukemia/myelodysplastic syndrome (AML/MDS). Mutation of DDX41 has been widely reported in various types of myeloid neoplasms. This systematic r…
• Risk factors analysis and nomogram development for myelosuppression in diffuse large B-cell lymphoma patients undergoing first-line chemotherapy: a dual-centre retrospective cohort study
  2025 · 碳中和与 CCUS · Objective: The primary objective of this research was to examine the characteristics of myelosuppression following first-line chemotherapy in patients suffering from diffuse large B-cell lymphoma (DLBCL). Furthermore, th…
• Leveraging Digital Twins for Stratification of Patients with Breast Cancer and Treatment Optimization in Geriatric Oncology: Multivariate Clustering Analysis
  2025 · 数字孪生 · Background: Defining optimal adjuvant therapeutic strategies for older adult patients with breast cancer remains a challenge, given that this population is often overlooked and underserved in clinical research and decisi…
• Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2- breast tumours
  2025 · 基因技术工具 · ER/PR+HER2- breast tumours are the most predominant subtype of breast cancer worldwide, including India. Unlike TNBCs, these tumours can be treated with anti-estrogens or aromatase inhibitors. Despite the success of endo…
• Comprehensive genomic profiling of over 10,000 advanced solid tumors
  2025 · 基因技术工具 · // Jean-Paul De La O 1 , Jess R. Hoag 1 , Angela K. Deem 1 , Min Wang 1 , Arthur Starodynov 1 , Sameer S. Udhane 1 , Janine R. LoBello 1 , Nishitha Therala 1 , David W. Hall 1 , Gargi D. Basu 1 and Frederick L. Baehner 1…
• A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer
  2025 · 基因技术工具 · The Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) study assessed the feasibility of using comprehensive genomic profiling (CGP) in clinical decision-making for patients with advanced cancers. Th…
• AI-Enabled Cancer Drug Discovery: Present Landscapes and 20-Year Outlook
  2025 · 量子材料 · Artificial intelligence (AI) is rapidly reshaping the landscape of cancer drug discovery, offering new computational paradigms that address long-standing challenges in target identification, compound design, safety evalu…
• AI-Enabled Cancer Drug Discovery: Present Landscapes and 20-Year Outlook
  2025 · 量子材料 · Artificial intelligence (AI) is rapidly reshaping the landscape of cancer drug discovery, offering new computational paradigms that address long-standing challenges in target identification, compound design, safety evalu…
• AI-based histopathology image analysis reveals a distinct subset of endometrial cancers
  2024 · AI 安全与对齐 · Endometrial cancer (EC) has four molecular subtypes with strong prognostic value and therapeutic implications. The most common subtype (NSMP; No Specific Molecular Profile) is assigned after exclusion of the defining fea…
• Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
  2024 · 生物计算 · BACKGROUND AND OBJECTIVE: Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Adva…
• Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis
  2024 · 生物计算 · Background With increasing recognition of the value of incorporating prognostic markers into amyotrophic lateral sclerosis (ALS) trial design and analysis plans, there is a pressing need to understand which among the pre…
• A Systematic Review on Artificial Intelligence Evaluating Metastatic Prostatic Cancer and Lymph Nodes on PSMA PET Scans
  2024 · 医疗人工智能 · Early detection of metastatic prostate cancer (mPCa) is crucial. Whilst the prostate-specific membrane antigen (PSMA) PET scan has high diagnostic accuracy, it suffers from inter-reader variability, and the time-consumin…
• Artificial intelligence innovations in neurosurgical oncology: a narrative review
  2024 · 医疗人工智能 · PURPOSE: Artificial Intelligence (AI) has become increasingly integrated clinically within neurosurgical oncology. This report reviews the cutting-edge technologies impacting tumor treatment and outcomes. METHODS: A rigo…
• Characterizing the Increase in Artificial Intelligence Content Detection in Oncology Scientific Abstracts From 2021 to 2023
  2024 · 医疗人工智能 · PURPOSE: Artificial intelligence (AI) models can generate scientific abstracts that are difficult to distinguish from the work of human authors. The use of AI in scientific writing and performance of AI detection tools a…
• Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer
  2024 · 医疗人工智能 · BACKGROUND: There is a need for clinically actionable prognostic and predictive tools to guide the management of oligometastatic castration-sensitive prostate cancer (omCSPC). METHODS: This is a multicenter retrospective…
• Artificial Intelligence and Statistical Models for the Prediction of Radiotherapy Toxicity in Prostate Cancer: A Systematic Review
  2024 · 医疗人工智能 · Background: Prostate cancer (PCa) is the second most common cancer in men, and radiotherapy (RT) is one of the main treatment options. Although effective, RT can cause toxic side effects. The accurate prediction of dosim…
• CHIP away at the marrow-clot connection: inflammation, clonal hematopoiesis, and thromboembolic disease
  2024 · 碳中和与 CCUS · ABSTRACT: Both the incidence and prognosis of arterial atherothrombosis and venous thromboembolism are strongly correlated with increasing age. Over the past decade, clonal hematopoiesis of indeterminate potential (CHIP)…
• Molecular prognostic of nine parthanatos death‐related genes in glioma, particularly in COL8A1 identification
  2024 · 碳中和与 CCUS · Post-operative progression and chemotherapy resistance are the main causes of treatment failure in glioma patients. There is a lack of ideal prediction models for post-operative glioma patient progression and drug sensit…
• Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides
  2024 · 深海科技 · PURPOSE Cancers with homologous recombination deficiency (HRD) can benefit from platinum salts and poly(ADP-ribose) polymerase inhibitors. Standard diagnostic tests for detecting HRD require molecular profiling, which is…
• Digital twins: a new paradigm in oncology in the era of big data
  2024 · 数字孪生 · Recent advancements in health care digitalization opened the collection and availability of big data, whose analysis requires artificial intelligence-based technologies to facilitate the development of predictive tools s…
• Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival
  2024 · 基因技术工具 · BACKGROUND: The 21-gene recurrence score (RS) assay (Oncotype DX) is used to guide adjuvant chemotherapy use for patients with hormone receptor-positive, HER2 (human epidermal growth factor receptor 2)-negative, axillary…
• Effect of different exercise types on quality of life in patients with breast cancer: A network meta-analysis of randomized controlled trials
  2024 · 生命科学 · BACKGROUND: Exercise is a rehabilitation strategy for patients with breast cancer; however, the optimal type of exercise remains uncertain. This study aimed to compare the effects of five exercise types on the quality of…
• Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma
  2024 · 核能 · We present a 54-year-old White male with a diagnosis of stage IV pancreatic neuroendocrine carcinoma. Next-generation sequencing of the tumor/blood identified a complex tumor genome, which included a rearranged during tr…
• An overview and a roadmap for artificial intelligence in hematology and oncology
  2023 · 医疗人工智能 · BACKGROUND: Artificial intelligence (AI) is influencing our society on many levels and has broad implications for the future practice of hematology and oncology. However, for many medical professionals and researchers, i…
• Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL
  2023 · 数字孪生 · Phase I oncology clinical trials often comprise a limited number of patients representing different disease subtypes who are divided into cohorts receiving treatment(s) at different dosing levels and schedules. Here, we …
• Clinical-AI-Demos: Humanoid and LLM Demos for Physical AI Oncology Clinical Trials
  2026 · AI Agent 生态 · Summary Delivered a comprehensive directory tree of code generation instructions at demo-projects/07-humanoid/paper/instructions/ extending demo prompt 07 (Humanoid 24/7 Adverse Event Response Team) with multi-robot syne…
• ITU and Cancer Biology: A Single-Axiom View of Cellular Breakdown, Metabolism, Immunology, and the 2026-2040 Treatment Roadmap
  2026 · 生物计算 · We apply the Information-Theoretic Unification (ITU) framework (Terada 2026, concept DOI 10.5281/zenodo.20109209; current version v2.0.0 at 10.5281/zenodo.20133709) to cancer biology. Cancer is re-expressed as the breakd…
• ITU and Cancer Biology: A Single-Axiom View of Cellular Breakdown, Metabolism, Immunology, and the 2026-2040 Treatment Roadmap
  2026 · 生物计算 · We apply the Information-Theoretic Unification (ITU) framework (Terada 2026, concept DOI 10.5281/zenodo.20109209; current version v2.0.0 at 10.5281/zenodo.20133709) to cancer biology. Cancer is re-expressed as the breakd…
• AI-Powered Liquid Biopsy Interpretation: A Systematic Literature Review
  2026 · 医疗人工智能 · Liquid biopsy has arisen as a revolutionary method in oncology, which permits non-invasive identification and tracking of cancer by means of circulating biomarkers including cell-free DNA, tumor cells in circulation, and…
• AI-Powered Liquid Biopsy Interpretation: A Systematic Literature Review
  2026 · 医疗人工智能 · Liquid biopsy has arisen as a revolutionary method in oncology, which permits non-invasive identification and tracking of cancer by means of circulating biomarkers including cell-free DNA, tumor cells in circulation, and…
• Digital Twins as catalysts for Whole Person Health Mind Body Medicine in Integrative Oncology
  2026 · 数字孪生 · Artificial intelligence and digital health technologies are reshaping oncology through increasingly personalized, predictive, and data-driven care. Among these innovations, medical Digital Twins - dynamic virtual softwar…
• Clinical-AI-Demos: Humanoid and LLM Demos for Physical AI Oncology Clinical Trials
  2026 · 具身智能 · Summary Delivered the executable counterpart to the v0.3.0 instructions tree at demo-projects/07-humanoid/paper/codegen/. The v0.4.0 codegen tree implements the v0.3.0 specifications as runnable Python, C++, Rust, YAML, …
• Clinical-AI-Demos: Humanoid and LLM Demos for Physical AI Oncology Clinical Trials
  2026 · 具身智能 · Summary Delivered the draft paper LaTeX scaffold at demo-projects/07-humanoid/paper/draft-paper/ for the upcoming paper "Triple Humanoid 24/7 Adverse Event Oncology Trial Response Team: 4-Site Rotation" by Kevin Kawchak …
• Clinical-AI-Demos: Humanoid and LLM Demos for Physical AI Oncology Clinical Trials
  2026 · 具身智能 · Summary Delivered the full paper LaTeX expansion at demo-projects/07-humanoid/paper/full-paper/ for the paper "Triple Humanoid 24/7 Adverse Event Oncology Trial Response Team: 4-Site Rotation" by Kevin Kawchak (ORCID 000…
• Clinical-AI-Demos: Humanoid and LLM Demos for Physical AI Oncology Clinical Trials
  2026 · 具身智能 · Summary Delivered a comprehensive directory tree of code generation instructions at demo-projects/07-humanoid/paper/instructions/ extending demo prompt 07 (Humanoid 24/7 Adverse Event Response Team) with multi-robot syne…
• Clinical-AI-Demos: Humanoid and LLM Demos for Physical AI Oncology Clinical Trials
  2026 · 具身智能 · Summary Delivered the executable runtime counterpart to the v0.4.0 codegen tree at demo-projects/07-humanoid/paper/execution/. The v0.5.0 execution tree captures the runtime outcomes of every executable element in the co…
• Clinical-AI-Demos: Humanoid and LLM Demos for Physical AI Oncology Clinical Trials
  2026 · 具身智能 · Summary Delivered the imagegen tree at demo-projects/07-humanoid/paper/imagegen/ for the paper "Triple Humanoid 24/7 Adverse Event Oncology Trial Response Team: 4-Site Rotation" by Kevin Kawchak (ORCID 0009-0007-5457-866…
• Clinical-AI-Demos: Humanoid and LLM Demos for Physical AI Oncology Clinical Trials
  2026 · 具身智能 · ## Summary Delivered the seminar presentation at pdac-presentation/ for the talk "LLM Pancreatic Oncology Clinical Trial System: Large Documents, Funding, and AI Peer Review" by Kevin Kawchak (ORCID 0009-0007-5457-8667, …
• Clinical-AI-Demos: Humanoid and LLM Demos for Physical AI Oncology Clinical Trials
  2026 · 具身智能 · ## Summary Delivered the seminar presentation at pdac-presentation/ for the talk "LLM Pancreatic Oncology Clinical Trial System: Large Documents, Funding, and AI Peer Review" by Kevin Kawchak (ORCID 0009-0007-5457-8667, …
• Vedanta 2.0: A Five-Part Philosophical Framework of Reality, Truth, Desire, Time, and Philosophical
  2026 · 生命科学 · Description Vedanta 2.0: A Five-Part Philosophical Framework of Reality, Truth, Desire, Time, and Philosophical Synthesis presents an integrated philosophical inquiry into five fundamental dimensions of human existence. …
• Vedanta 2.0: A Five-Part Philosophical Framework of Reality, Truth, Desire, Time, and Philosophical
  2026 · 生命科学 · Description Vedanta 2.0: A Five-Part Philosophical Framework of Reality, Truth, Desire, Time, and Philosophical Synthesis presents an integrated philosophical inquiry into five fundamental dimensions of human existence. …
• Vedanta 2.0: A Five-Part Philosophical Framework of Reality, Truth, Desire, Time, and Philosophical
  2026 · 生命科学 · Description Vedanta 2.0: A Five-Part Philosophical Framework of Reality, Truth, Desire, Time, and Philosophical Synthesis presents an integrated philosophical inquiry into five fundamental dimensions of human existence. …
• Vedanta 2.0: A Five-Part Philosophical Framework of Reality, Truth, Desire, Time, and Philosophical
  2026 · 生命科学 · Description Vedanta 2.0: A Five-Part Philosophical Framework of Reality, Truth, Desire, Time, and Philosophical Synthesis presents an integrated philosophical inquiry into five fundamental dimensions of human existence. …
• Vedanta 2.0: A Five-Part Philosophical Framework of Reality, Truth, Desire, Time, and Philosophical
  2026 · 生命科学 · Description Vedanta 2.0: A Five-Part Philosophical Framework of Reality, Truth, Desire, Time, and Philosophical Synthesis presents an integrated philosophical inquiry into five fundamental dimensions of human existence. …
• Vedanta 2.0: A Five-Part Philosophical Framework of Reality, Truth, Desire, Time, and Philosophical
  2026 · 生命科学 · Description Vedanta 2.0: A Five-Part Philosophical Framework of Reality, Truth, Desire, Time, and Philosophical Synthesis presents an integrated philosophical inquiry into five fundamental dimensions of human existence. …
• Phase-Dependent Therapeutic Efficacy in Oncology: External Clinical Convergence with Reset-Window Dynamics
  2026 · 生命科学 · This Conceptual Note is part of the URM / Dynamic Medicine Series and interprets phase-dependent therapeutic efficacy in oncology as external clinical convergence with Reset-Window dynamics. The article is prompted by a …
• Phase-Dependent Therapeutic Efficacy in Oncology: External Clinical Convergence with Reset-Window Dynamics
  2026 · 生命科学 · This Conceptual Note is part of the URM / Dynamic Medicine Series and interprets phase-dependent therapeutic efficacy in oncology as external clinical convergence with Reset-Window dynamics. The article is prompted by a …

以 API 获取该主题全量数据

# 主题词表（含本主题的站点分布与年度分布）
curl http://data.swarmlabs.tools/api/topics.json

# 主题共现知识图谱
curl http://data.swarmlabs.tools/api/graph.json

需要按主题批量拉取、导出 BibTeX 或接入 AI Agent？查看 数据下载与格式 或 MCP 接入。